摘要:
The present invention relates to a method for quantitatively measuring the muscular relaxing activity of a neurotoxin. Specifically, based on an extent of the activity of muscular relaxation of a neurotoxin from bacteria of Clostridium , the present invention relates to a method for quantification of the efficacy (potential and/or diffusion reaction) of a neurotoxin comprising the following steps of: (a) administering a neurotoxin to the hind leg muscle of one of hind legs of a non-human mammal; (b) applying electric stimulus to said non-human mammal; (c) measuring a compound muscle action potential (CMAP) by contraction of said hind leg muscle to which the neurotoxin is administered and/or of the hind leg muscle of the other hind leg to which the neurotoxin is not administered; and (d) taking amplitude data from the compound muscle action potential (CMAP) obtained by the measurement in step (c) and analyzing an extent of a decrease in amplitude to thereby quantify the efficacy of the muscular relaxing activity by the neurotoxin. In contrast to the mouse LD 50 currently used as a potential unit of a botulinum toxin which is measurable at a level of only several units, the quantification method of the efficacy of a neurotoxin of the present invention allows for measurement at a level of as low as 0.01 to 1 unit and hence is a method with a high sensitivity, reproducibility and accuracy.
摘要:
A method of quantitatively measuring the muscle relaxant action of a neurotoxin. More specifically speaking, a method of quantifying the efficacy (titer and/or diffusion reaction) of a neurotoxin based on the degree of the muscle relaxant action of a neurotoxin originating in a bacterium belonging to the genus Clostridium, which is characterized by comprising: (a) administering the neurotoxin to one hinder leg of a nonhuman mammal; (b) electrically stimulating the nonhuman mammal; (c) measuring the compound muscle action potential (CMAP) caused by the contraction of muscles in the hinder leg to which the neurotoxin has been administered and/or muscles in the other hinder leg to which the neurotoxin has not been administered by using an electromyograph; and (d) taking out the amplitude data from the compound muscle action potential (CMAP) obtained by the measurement in the step (c) and analyzing the degree of a decrease in the amplitude to thereby quantify the efficacy of the muscle relaxant action by the neurotoxin. Although mouse LD50 that has been employed as a titer unit of the botulin toxin allows the measurement only at a several unit level, the above-described method of quantifying the efficacy of a neurotoxin enables the measurement at 0.01 to 1 unit level. That is, this method is excellent in sensitivity, reproducibility and accuracy.
摘要:
A novel type A botulinum toxin preparation is provided. A neuromuscular transmission blocking agent comprising as an active ingredient a highly purified type A botulinum toxin from Clostridium botulinum as infant botulism pathogen and a medicament for treating a disease with a muscle overactivity comprising as an active ingredient said toxin. In particular, the medicament of the present invention, as compared to the conventional known botulinum toxin preparations, has rapid efficacy of potential and is less diffusive and thus, having a broader safety margin, may be used as therapeutic medicament for decreasing local, muscle overactivity in a disease with a muscle overactivity.